» Articles » PMID: 25552308

SOD1 Overexpression Prevents Acute Hyperglycemia-induced Cerebral Myogenic Dysfunction: Relevance to Contralateral Hemisphere and Stroke Outcomes

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Admission hyperglycemia (HG) amplifies vascular injury and neurological deficits in acute ischemic stroke, but the mechanisms remain controversial. We recently reported that ischemia-reperfusion (I/R) injury impairs the myogenic response in both hemispheres via increased nitration. However, whether HG amplifies contralateral myogenic dysfunction and whether loss of tone in the contralateral hemisphere contributes to stroke outcomes remain to be determined. Our hypothesis was that contralateral myogenic dysfunction worsens stroke outcomes after acute hyperglycemic stroke in an oxidative stress-dependent manner. Male wild-type or SOD1 transgenic rats were injected with saline or 40% glucose solution 10 min before surgery and then subjected to 30 min of ischemia/45 min or 24 h of reperfusion. In another set of animals (n = 5), SOD1 was overexpressed only in the contralateral hemisphere by stereotaxic adenovirus injection 2-3 wk before I/R. Myogenic tone and neurovascular outcomes were determined. HG exacerbated myogenic dysfunction in contralateral side only, which was associated with infarct size expansion, increased edema, and more pronounced neurological deficit. Global and selective SOD1 overexpression restored myogenic reactivity in ipsilateral and contralateral sides, respectively, and enhanced neurovascular outcomes. In conclusion, our results show that SOD1 overexpression nullified the detrimental effects of HG on myogenic tone and stroke outcomes and that the contralateral hemisphere may be a novel target for the management of acute hyperglycemic stroke.

Citing Articles

Detrimental effects of transient cerebral ischemia on middle cerebral artery mitochondria in female rats.

Rutkai I, Merdzo I, Wunnava S, McNulty C, Chandra P, Katakam P Am J Physiol Heart Circ Physiol. 2022; 323(6):H1343-H1351.

PMID: 36367688 PMC: 9744641. DOI: 10.1152/ajpheart.00346.2022.


Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.

Tyagi R, Vaidya B, Sharma S Pharmacol Rep. 2022; 74(5):790-817.

PMID: 36149598 DOI: 10.1007/s43440-022-00417-5.


New insights into targeting mitochondria in ischemic injury.

Jia J, Jin H, Nan D, Yu W, Huang Y Apoptosis. 2021; 26(3-4):163-183.

PMID: 33751318 DOI: 10.1007/s10495-021-01661-5.


Mitochondrial targeting as a novel therapy for stroke.

Russo E, Nguyen H, Lippert T, Tuazon J, Borlongan C, Napoli E Brain Circ. 2018; 4(3):84-94.

PMID: 30450413 PMC: 6187947. DOI: 10.4103/bc.bc_14_18.


Understanding the Role of Dysfunctional and Healthy Mitochondria in Stroke Pathology and Its Treatment.

Nguyen H, Zarriello S, Rajani M, Tuazon J, Napoli E, Borlongan C Int J Mol Sci. 2018; 19(7).

PMID: 30037107 PMC: 6073421. DOI: 10.3390/ijms19072127.


References
1.
Cipolla M, Lessov N, Hammer E, CURRY A . Threshold duration of ischemia for myogenic tone in middle cerebral arteries: effect on vascular smooth muscle actin. Stroke. 2001; 32(7):1658-64. DOI: 10.1161/01.str.32.7.1658. View

2.
Kamada H, Yu F, Nito C, Chan P . Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke. 2007; 38(3):1044-9. PMC: 1828129. DOI: 10.1161/01.STR.0000258041.75739.cb. View

3.
Noshita N, Sugawara T, Lewen A, Hayashi T, Chan P . Copper-zinc superoxide dismutase affects Akt activation after transient focal cerebral ischemia in mice. Stroke. 2003; 34(6):1513-8. DOI: 10.1161/01.STR.0000072986.46924.F4. View

4.
Scott J, Robinson G, French J, OConnell J, Alberti K, Gray C . Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet. 1999; 353(9150):376-7. DOI: 10.1016/s0140-6736(05)74948-5. View

5.
Hafez S, Coucha M, Bruno A, Fagan S, Ergul A . Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res. 2014; 5(4):442-453. PMC: 4112106. DOI: 10.1007/s12975-014-0336-z. View